


Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma (*RI version*)

Authors:

Sven Neubert^{1*}, Umair Munawar^{1*}, Julia Mersi¹, Julia Noderer¹, Silvia Nerreter¹, Shilpa Kurian¹, Seungbin Han¹, Christina Verbruggen¹, Emma Besant¹, Nina Rein¹, Max Köppel¹, Johanna Lehmann¹, Tabea Köhler¹, Hannah Labinsky¹, Sigrun Häusl¹, Yoko Tamamushi¹, Xiang Zhou¹, Jule Pinter², Anna Laura Herzog², Kai Lopau², Elion Hoxha², Christoph Rummelt³, Elena Gerhard-Hartmann⁴, Andreas Rosenwald⁴, Torsten Steinbrunn¹, Thomas Nerreter¹, Michael Hudecek¹, Hermann Einsele¹, Leo Rasche^{1,5}, K. Martin Kortüm^{1,†}, Johannes M. Waldschmidt^{1,6,†}

SUPPLEMENT

Supplementary Figure 1



Suppl. Figure 1. sBCMA impairs the cytolytic activity of anti-BCMA CAR T-cells.

OPM-2 cells were co-cultured with (A) cilta-cel or (B) BCMA-CAR T-cells at different E:T cell ratios. Soluble BCMA was titrated across different conditions (0-1000 nM) and cytolytic activity was measured using a luminescence-based viability assay. Data for each condition were normalized to Mock CAR T-cells at the corresponding E:T ratio. *Abbreviations:* *cilta-cel*= *ciltacabtagene autoleucel*, *BCMA*= *B-cell maturation antigen*, *CAR*=*chimeric antigen receptor*, *E:T*= *effector:target*